NewSpring Capital / NewSpring Growth
Sorcero says NewSpring Growth led $42.5M Series B
Summary: Sorcero announced a $42.5 million Series B financing led by NewSpring Growth, described in the source as NewSpring Capital's dedicated growth equity strategy. The Sorcero source says Leawood Venture Capital and Blu Ventures joined the round and that total capital raised reached $59 million.
Why it matters: The update may matter to due-diligence readers as a public NewSpring Growth activity signal in life-sciences software, while the source should not be used to validate Sorcero's AI platform, customer adoption, clinical utility, valuation, fund exposure, returns, or investment merit.
Summary
Sorcero announced that it secured $42.5 million in Series B financing led by NewSpring Growth, which the Sorcero source describes as NewSpring Capital’s dedicated growth equity strategy. The announcement says Leawood Venture Capital and Blu Ventures joined the round and that the financing brought Sorcero’s total capital raised to $59 million.
Sorcero’s release says the financing was intended to accelerate expansion across medical affairs, safety, scientific communications, and medical-device segments globally. This draft treats the item as dated November 2025 seed/backfill coverage from a portfolio-company source, not as current August 2026 news or as proof of AI-product efficacy, customer adoption, clinical utility, regulatory effectiveness, valuation, ownership, fund performance, or investment merit.
Why it matters
For due-diligence readers, the useful signal is that NewSpring Growth is publicly named as lead investor in a life-sciences software financing with named co-investors and stated expansion areas. Manager-specific activity in growth equity can help readers monitor sector focus, capital-stage exposure, co-investor networks, and the types of portfolio-company themes a manager is publicly supporting.
The signal is bounded. Sorcero’s source supports the announced round, lead-investor language, co-investors, total-capital-raised statement, and expansion framing. It does not independently validate Sorcero’s technology, customer outcomes, regulatory impact, product quality, commercial adoption, valuation, ownership allocation, fund-level exposure, returns, or investor suitability.
Source notes
- Sorcero source-party announcement: https://www.sorcero.com/sorcero-secures-42.5m-series-b-financing-led-by-newspring-capital-to-scale-its-ai-platform-accelerate-expansion-across-life-sciences
- Sorcero newsroom listing: https://www.sorcero.com/company/newsroom
- Source posture: primary portfolio-company announcement and source-party newsroom listing, suitable for source-attributed facts about the November 21, 2025 date, $42.5 million Series B, NewSpring Growth/NewSpring Capital role, Leawood Venture Capital and Blu Ventures participation, total-capital-raised statement, expansion segments, and Hart Callahan/NewSpring quote context.
- Verifier posture: the 2026-08-13 PM source reviewer recovered body-level support from Sorcero’s official domain and reported no same-event local post or draft at the time of review. The attempted PR Newswire URL returned 404 and is not cited here.
- Editorial caveat: this is dated backfill and same-manager clustered with other NewSpring items. Keep AI, product, customer, medical-affairs, safety, and expansion claims attributed to Sorcero and avoid treating the announcement as independent validation.
9AT filing context
Public adviser/profile context reviewed by 9AT maps NewSpring Capital to CRD 160608 / SEC file 801-73849, with Radnor, Pennsylvania adviser identity, public domain newspringcapital.com, and about $3.3 billion in reported ADV regulatory AUM/profile scale. That context is useful only as broad adviser/platform identity background.
The same public adviser/profile context may support broad NewSpring growth and healthcare platform background, but it should not be used to identify a specific investing vehicle unless a public source names the vehicle. The $42.5 million Series B, NewSpring Growth lead role, co-investor names, total-capital-raised statement, and expansion plans should remain attributed to Sorcero’s source-party release.
No 13F or Form 5500 context is included. The analyst handoff reported no public 13F filer for NewSpring in this pass, and employee-benefit-plan filings do not add useful context to a private Series B financing announcement.
What to watch
Watch for later Sorcero, NewSpring, Leawood Venture Capital, Blu Ventures, or transaction-party disclosures that clarify the exact NewSpring vehicle, closing status, governance, product milestones, customer categories, regulatory context, or additional financing.
Future coverage should avoid treating the November 2025 announcement as evidence that Sorcero’s platform works as described or that customers, regulators, or investors have validated its claims. Any such follow-up should be separately source-backed and clearly distinguished from NewSpring adviser/profile background.